Distribution of Yeast Isolates from Invasive Infections and Their In Vitro Susceptibility to Antifungal Agents: Evidence from 299 Cases in a 3-Year (2010 to 2012) Surveillance Study

Mycopathologia

Volumn 179, Issue 5-6, 2015, Pages 397-405

  Li, Wei ^a   Hu, Yu an ^a   Li, Fang qiu ^a   Shi, Li ning ^a   Shao, Hai feng ^a   Huang, Mei ^a   Wang, Ying ^a   Han, Dan dan ^a   Liao, Hong ^a   Ma, Chun fang ^a   Zhang, Guo yong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Antifungal susceptibility; Distribution of species; Yeast infection

Indexed keywords

ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; CANDIDA; CHILD; CHINA; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; FEMALE; FILOBASIDIELLA; FUNGEMIA; HOSPITAL; HUMAN; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CHILD; CHILD, PRESCHOOL; CHINA; CRYPTOCOCCUS; EPIDEMIOLOGICAL MONITORING; FEMALE; FUNGEMIA; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84939962683     PISSN: 0301486X     EISSN: 15730832     Source Type: Journal    
DOI: 10.1007/s11046-015-9858-5     Document Type: Article

References (40)

1. Sifuentes-Osornio J, Corzo-Leon DE, Ponce-De-Leon LA. Epidemiology of invasive fungal infections in Latin America. Curr Fungal Infect Rep. 2012;6:23–34.
2. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175–91.
3. Liao Y, Chen M, Hartmann T, Yang RY, Liao WQ. Epidemiology of opportunistic invasive fungal infections in China: review of literature. Chin Med J (Engl). 2013;126:361–8.
4. Asweih N, Khan ZU, Ahmad S, Devarajan L, Khan S, Joseph L, et al. Kodamaea ohmeri as an emerging pathogen: a case report and review of the literature. Med Mycol. 2011;49:766–70.
5. Wirth F, Goldani LZ. Epidemiology of Rhodotorula: an emerging pathogen. Interdiscip Perspect Infect Dis. 2012;2012:465717.
6. Morace G, Borghi E. Fungal infections in ICU patients: epidemiology and the role of diagnostics. Minerva Anestesiol. 2010;76:950–6.
7. Almeida AA, Mesquita CS, Svidzinski TI, Oliveira KM. Antifungal susceptibility and distribution of Candida spp. isolates from the University Hospital in the municipality of Dourados, State of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop. 2013;46:335–9.
8. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14:954–66.
9. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets. 2006;7:495–504.
10. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(Suppl 1):1–10.
11. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006;44:819–26.
12. Panizo MM, Reviákina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol. 2009;47:137–43.
13. Clinical and Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of yeasts: approved standard, M44-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2004.
14. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol. 2005;43:5848–59.
15. Hazen KC, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol. 2003;41:5623–32.
16. Clinical and Laboratory Standards Institute. Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints and quality control limits for antifungal disk diffusion susceptibility testing of yeasts: informational supplement (M44-S2). Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
17. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19:435–47.
18. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006;44:819–26.
19. Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol. 2012;50:3952–9.
20. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48:1366–77.
21. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–63.
22. Shivaprakasha S, Radhakrishnan K, Karim PM. Candida spp. other than Candidaalbicans: a major cause of fungaemia in a tertiary care centre. Indian J Med Microbiol. 2007;25:405–7.
23. Adhikary R, Joshi S. Species distribution and antifungal susceptibility of candidemia at a multi super specialty centre in Southern India. Indian J Med Microbiol. 2011;29:309–11.
24. Xess I, Jain N, Hasan F, Mandal P, Banerjee U. Epidemiology of candidemia in a tertiary care centre of North India: 5-year study. Infection. 2007;35:256–9.
25. Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:2816–23.
26. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother. 2011;55:561–6.
27. Horasan ES, Ersöz G, Göksu M, Otag F, Kurt AO, Karaçorlu S, et al. Increase in Candida parapsilosis fungemia in critical care units: a 6-years study. Mycopathologia. 2010;170:263–8.
28. Trofa D, Gacser A, Nosanchuk JD. Candidaparapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21:606–25.
29. Li F, Wu L, Cao B, Zhang Y, Li X, Liu Y. Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis. 2013;13:353.
30. Mcginnis MR, Walker DH, Folds JD. Hansenula polymorpha infection in a child with chronic granulomatous disease. Arch Pathol Lab Med. 1980;104:290–2.
31. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002;40:1298–302.
32. Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol. 2009;47:3185–90.
33. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsåker T, Gaustad P, et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006;44:1977–81.
34. Quindos G, Abarca L, Carrillo-Muñoz AJ, Arévalo MP, Bornay FJ, Casals JB, et al. Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. Rev Iberoam Micol. 1999;16:97–100.
35. Abbes S, Mary C, Sellami H, Michel-Nguyen A, Ayadi A, Ranque S. Interactions between copy number and expression level of genes involved in fluconazole resistance in Candidaglabrata. Front Cell Infect Microbiol. 2013;3:74.
36. Farahyar S, Zaini F, Kordbacheh P, Rezaie S, Safara M, Raoofian R, et al. Overexpression of aldo-keto-reductase in azole-resistant clinical isolates of Candidaglabrata determined by cDNA-AFLP. Daru. 2013;21:1.
37. Wu J, Guo H, Yi G, Zhou L, He X, Huang X, et al. Prevalent drug resistance among oral yeasts from asymptomatic patients in Hainan, China. Mycopathologia. 2014;177:299–307.
38. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 2004;42:3142–6.
39. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743–6.
40. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009;47:117–23.